Explore the categories so you can find more about your search.

Categorie > Blood / Hematology

New Meta-Analysis Confirms Safety Profile For NeoRecormon In Treating Anaemia In Cancer Patients

Categorie : Blood / Hematology
Data Published in the British Journal of Cancer Reports That NeoRecormon use has no Negative Impact on Overall Survival or Tumour Progression A new meta-analysis of all 12 prospective, randomised, controlled studies in 2,301 cancer patients shows that treating anaemia with NeoRecormon(R) (epoeti ...

read more Data Published in the British Journal of Cancer Reports That NeoRecormon use has no Negative Impact on Overall Survival or Tumour Progression A new meta-analysis of all 12 prospective, randomised, controlled studies in 2,301 cancer patients shows that treating anaemia with NeoRecormon(R) (epoeti read more Thu Jun 2008 Thu Jun 2008

Bristol-Myers Squibb And Pfizer Initiate New Study In The Apixaban Phase 3 Clinical Trial Program

Categorie : Blood / Hematology
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced the start of a new Phase 3 clinical trial to assess the effect of apixaban in patients with venous thromboembolism (VTE), a potentially fatal disease process that begins with blood clots in the leg veins or lungs. ...

read more Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced the start of a new Phase 3 clinical trial to assess the effect of apixaban in patients with venous thromboembolism (VTE), a potentially fatal disease process that begins with blood clots in the leg veins or lungs. read more Thu Jun 2008 Thu Jun 2008

Many Happy Returns For National Blood Donor Week, Canada

Categorie : Blood / Hematology
Today marks the beginning of the first National Blood Donor Week recognized by the Government of Canada. ...

read more Today marks the beginning of the first National Blood Donor Week recognized by the Government of Canada. read more Thu Jun 2008 Thu Jun 2008

A Blood Substitute's Effectiveness And Safety Addressed In Large Clinical Trial

Categorie : Blood / Hematology
A predicted shortfall of over 4 million units of blood worldwide is driving the need to develop an alternative to red blood cells.Academic and industry researchers participated in a Phase III multi-center clinical trial and found that use of a blood substitute was relatively safe in patients under 8 ...

read more A predicted shortfall of over 4 million units of blood worldwide is driving the need to develop an alternative to red blood cells.Academic and industry researchers participated in a Phase III multi-center clinical trial and found that use of a blood substitute was relatively safe in patients under 8 read more Thu Jun 2008 Thu Jun 2008

AMT Makes Important Advance In The Development Of Its Gene Therapy For Hemophilia B -Company Accesses Technology To Prevent Immune Response

Categorie : Blood / Hematology
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced that it obtained a license from 'TIGET' San Raffaele Telethon Institute For Gene Therapy, Italy, to use their micro-RNA technology to prevent immune responses against gene therapy for Hemophi ...

read more Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced that it obtained a license from 'TIGET' San Raffaele Telethon Institute For Gene Therapy, Italy, to use their micro-RNA technology to prevent immune responses against gene therapy for Hemophi read more Thu Jun 2008 Thu Jun 2008

Health Economic Analysis Reports That Revlimid Is A Cost Effective Treatment For Multiple Myeloma

Categorie : Blood / Hematology
Celgene International Sarl (Nasdaq:CELG) announced that data presented at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark found that patients previously treated for multiple myeloma receiving REVLIMID (lenalidomide) in combination with dexamethasone experienced ...

read more Celgene International Sarl (Nasdaq:CELG) announced that data presented at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark found that patients previously treated for multiple myeloma receiving REVLIMID (lenalidomide) in combination with dexamethasone experienced read more Thu Jun 2008 Thu Jun 2008

Romiplostim Data Show Potential Long-Term Efficacy And Safety In Adults With Chronic ITP

Categorie : Blood / Hematology
Amgen Inc. (NASDAQ: AMGN) announced updated results from the ongoing, open-label extension study on the long-term safety and efficacy of romiplostim in adult patients with chronic immune thrombocytopenic purpura (ITP), a chronic and serious autoimmune disorder characterized by low platelet counts in ...

read more Amgen Inc. (NASDAQ: AMGN) announced updated results from the ongoing, open-label extension study on the long-term safety and efficacy of romiplostim in adult patients with chronic immune thrombocytopenic purpura (ITP), a chronic and serious autoimmune disorder characterized by low platelet counts in read more Thu Jun 2008 Thu Jun 2008

New Molecular Insight Into Amboebic Dysentery

Categorie : Blood / Hematology
In the June 15th issue of G&D, Dr. Sinisa Urban (Johns Hopkins University School of Medicine) and colleagues reveal a potential role for the rhomboid enzyme, EhROM1, in the pathogenesis of the enteric protozoan parasite, E. histolytica. This discovery posits EhROM1 as a prospective target in the tre ...

read more In the June 15th issue of G&D, Dr. Sinisa Urban (Johns Hopkins University School of Medicine) and colleagues reveal a potential role for the rhomboid enzyme, EhROM1, in the pathogenesis of the enteric protozoan parasite, E. histolytica. This discovery posits EhROM1 as a prospective target in the tre read more Thu Jun 2008 Thu Jun 2008

Multiple Myeloma - Velcade(R) (bortezomib), 30% Complete Response Rate Compared To 4 Percent With Current Drug Treatment Standard Of Care

Categorie : Blood / Hematology
Abstract Number: 0473 Janssen-Cilag / Ortho Biotech, the biopharmaceutical division of Janssen-Cilag, today announced unprecedented results from a registration-enabling phase III trial evaluating the VELCADE-based therapy with melphalan and prednisone (VMP) compared with melphalan and prednisone ...

read more Abstract Number: 0473 Janssen-Cilag / Ortho Biotech, the biopharmaceutical division of Janssen-Cilag, today announced unprecedented results from a registration-enabling phase III trial evaluating the VELCADE-based therapy with melphalan and prednisone (VMP) compared with melphalan and prednisone read more Thu Jun 2008 Thu Jun 2008

Risk Of Contamination From Unsafe Blood - China And United Arab Emirates Make Rapid Progress

Categorie : Blood / Hematology
China and the United Arab Emirates (UAE) have made impressive strides in tackling the risk of contamination from unsafe blood by reaching close to 100% voluntary blood donation , said the World Health Organization today . Their efforts to increase their safe blood base will be promoted as models for ...

read more China and the United Arab Emirates (UAE) have made impressive strides in tackling the risk of contamination from unsafe blood by reaching close to 100% voluntary blood donation , said the World Health Organization today . Their efforts to increase their safe blood base will be promoted as models for read more Thu Jun 2008 Thu Jun 2008

Romiplostim Data Show Potential Long-Term Efficacy And Safety In Adults With Chronic Immune Thrombocytopenic Purpura (ITP)

Categorie : Blood / Hematology
Amgen Inc. (NASDAQ: AMGN) announced updated results from the ongoing, open-label extension study on the long-term safety and efficacy of romiplostim in adult patients with chronic immune thrombocytopenic purpura (ITP), a chronic and serious autoimmune disorder characterized by low platelet counts i ...

read more Amgen Inc. (NASDAQ: AMGN) announced updated results from the ongoing, open-label extension study on the long-term safety and efficacy of romiplostim in adult patients with chronic immune thrombocytopenic purpura (ITP), a chronic and serious autoimmune disorder characterized by low platelet counts i read more Thu Jun 2008 Thu Jun 2008

New Analysis Shows That REVLIMID® Plus Dexamethasone Yielded A Mean Survival Of 5.6 Years For Patients With Multiple Myeloma

Categorie : Blood / Hematology
Celgene Corporation (NASDAQ: CELG) has announced that according to data from a pooled study presented at the 13th European Hematology Association (EHA) congress in Copenhagen, Denmark, multiple myeloma patients taking REVLIMID® (lenalidomide) plus dexamethasone significantly increased their survival ...

read more Celgene Corporation (NASDAQ: CELG) has announced that according to data from a pooled study presented at the 13th European Hematology Association (EHA) congress in Copenhagen, Denmark, multiple myeloma patients taking REVLIMID® (lenalidomide) plus dexamethasone significantly increased their survival read more Thu Jun 2008 Thu Jun 2008

Health Economic Analysis Reports That REVLIMID Is A Cost-Effective Treatment For Multiple Myeloma

Categorie : Blood / Hematology
Celgene Corporation (NASDAQ: CELG) announced that data presented recently at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark showed that the use of REVLIMID and dexamethasone was cost-effective with the incremental cost-effectiveness threshold ranging from £20, ...

read more Celgene Corporation (NASDAQ: CELG) announced that data presented recently at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark showed that the use of REVLIMID and dexamethasone was cost-effective with the incremental cost-effectiveness threshold ranging from £20, read more Thu Jun 2008 Thu Jun 2008

Some Northern California Colleges Banning Campus Blood Drives Because Of FDA's Policy Barring MSM

Categorie : Blood / Hematology
Some colleges in Northern California have banned campus blood drives, saying that FDA's lifetime ban on donations from men who have had sex with men violates the schools' nondiscrimination policies, NPR's "All Things Considered" reports. ...

read more Some colleges in Northern California have banned campus blood drives, saying that FDA's lifetime ban on donations from men who have had sex with men violates the schools' nondiscrimination policies, NPR's read more Thu Jun 2008 Thu Jun 2008

Positive Clinical Data For PBI-1402 Presented At The Annual Congress Of The European Hematology Association

Categorie : Blood / Hematology
ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") presented results on its orally-active PBI-1402 compound in clinical trial in patients with chemotherapy-induced anemia ("CIA") at the 13th Congress of the European Hematology Association held in Copenhagen, Denmark this week.Dr. Lyne Gagnon, ProMe ...

read more ProMetic Life Sciences Inc. (TSX:PLI) ( read more Thu Jun 2008 Thu Jun 2008

China, UAE Make Big Progress In Ensuring Safe Blood Donation

Categorie : Blood / Hematology
China and the United Arab Emirates (UAE) have made impressive strides in tackling the risk of contamination from unsafe blood by reaching close to 100% voluntary blood donation, said WHO today . Their efforts to increase their safe blood base will be promoted as models for other countries to follow ...

read more China and the United Arab Emirates (UAE) have made impressive strides in tackling the risk of contamination from unsafe blood by reaching close to 100% voluntary blood donation, said WHO today . Their efforts to increase their safe blood base will be promoted as models for other countries to follow read more Thu Jun 2008 Thu Jun 2008

Soliris® Improved Fatigue Independent Of Changes In Anemia In Patients With PNH By Controlling Hemolysis

Categorie : Blood / Hematology
Soliris® (eculizumab) therapy improved the often disabling fatigue experienced by patients with the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH) independent of improvements in anemia, according to data presented at the European Hematology Association (EHA) 13th Congress in Copenhage ...

read more Soliris® (eculizumab) therapy improved the often disabling fatigue experienced by patients with the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH) independent of improvements in anemia, according to data presented at the European Hematology Association (EHA) 13th Congress in Copenhage read more Thu Jun 2008 Thu Jun 2008

Revolade® (Eltrombopag) Data Presented At EHA: Updated Data For Extend Plus New Data For Repeat And Delphi Studies

Categorie : Blood / Hematology
GlaxoSmithKline has announced data on the long-term safety and efficacy of its investigational drug Revolade® (eltrombopag) for the treatment of chronic idiopathic thrombocytopenic purpura (ITP).1 Results from the ongoing, open label EXTEND (Eltrombopag eXTENded Dosing) (Abstract 0949) study showed ...

read more GlaxoSmithKline has announced data on the long-term safety and efficacy of its investigational drug Revolade® (eltrombopag) for the treatment of chronic idiopathic thrombocytopenic purpura (ITP).1 Results from the ongoing, open label EXTEND (Eltrombopag eXTENded Dosing) (Abstract 0949) study showed read more Thu Jun 2008 Thu Jun 2008

Unsafe Blood Transfusions, Medical Practices In Central Asia Contributing To Spread Of Infectious Diseases, Including HIV, World Bank Report Says

Categorie : Blood / Hematology
Unsafe blood transfusion services and medical practices in Central Asian countries are contributing to the spread of HIV and other infectious diseases in the region, according to a report recently released by the World Bank, Kazakhstan Today/Gazeta.kz reports. ...

read more Unsafe blood transfusion services and medical practices in Central Asian countries are contributing to the spread of HIV and other infectious diseases in the region, according to a report recently released by the World Bank, Kazakhstan Today/Gazeta.kz reports. read more Thu Jun 2008 Thu Jun 2008

Assembly Of Molecules Critical To Protein Function Witnessed By Researchers

Categorie : Blood / Hematology
A Virginia Tech research group lead by two biochemistry graduate students has isolated proteins responsible for the iron-sulfur cluster assembly process and witnessed the necessary protein interactions in vivo - within a cell. They have captured pathway intermediates and observed protein interaction ...

read more A Virginia Tech research group lead by two biochemistry graduate students has isolated proteins responsible for the iron-sulfur cluster assembly process and witnessed the necessary protein interactions in vivo - within a cell. They have captured pathway intermediates and observed protein interaction read more Thu Jun 2008 Thu Jun 2008

<<< previous | 1 | 2 | 3 | 4 | 5 | 6 next >>>



     


Custom Search